Brain 17 Vienna
ALK fusion genes
• Found in around 5% of NSCLC
• Encountered more frequently in never smokers, the adenocarcinoma subtype, and in younger patients
• NSCLC patients with ALK rearrangement have improved OS after radiotherapy for brain metastases compared with EGFR or KRAS mutations => Subsequent receipt of targeted therapy is associated with additional improvement in OS
• Crizotinib : first approved ALK inhibitor
Shaw et al. J Clin Oncol 2009 Mak et al. Neuro Oncol 2015 Shaw et al. New Engl J Med 2013
Made with FlippingBook - Online catalogs